Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

NCT04010071 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking Union Medical College Hospital

Collaborators